AAAAAA
Results:
1-17
|
Results: 17
Authors:
MESSORI A
TRIPPOLI S
Citation: A. Messori et S. Trippoli, COMMENT - COST-EFFECTIVE PHARMACEUTICAL CARE FOR HIV DISEASE - REPLY, The Annals of pharmacotherapy, 32(6), 1998, pp. 716-717
Authors:
TRIPPOLI S
MESSORI A
BECAGLI P
ALTERINI R
TENDI E
Citation: S. Trippoli et al., TREATMENTS FOR NEWLY-DIAGNOSED MULTIPLE-MYELOMA - ANALYSIS OF SURVIVAL-DATA AND COST-EFFECTIVENESS EVALUATION, Oncology Reports, 5(6), 1998, pp. 1475-1482
Authors:
MESSORI A
TRIPPOLI S
BECAGLI P
TENDI E
Citation: A. Messori et al., TREATMENTS FOR NEWLY-DIAGNOSED ADVANCED OVARIAN-CANCER - ANALYSIS OF SURVIVAL-DATA AND COST-EFFECTIVENESS EVALUATION, Anti-cancer drugs, 9(6), 1998, pp. 491-502
Authors:
MESSORI A
TRIPPOLI S
Citation: A. Messori et S. Trippoli, CAN THE Q-TWIST METHOD PROVIDE INFORMATION ON PATIENTS PREFERENCES WITHOUT COLLECTING PREFERENCE DATA FROM THE PATIENTS, Journal of clinical oncology, 16(11), 1998, pp. 3716-3717
Authors:
MESSORI A
TRIPPOLI S
BECAGLI P
CINCOTTA M
LABBATE MG
ZACCARA G
Citation: A. Messori et al., ADJUNCTIVE LAMOTRIGINE THERAPY IN PATIENTS WITH REFRACTORY SEIZURES -A LIFETIME COST-UTILITY ANALYSIS, European Journal of Clinical Pharmacology, 53(6), 1998, pp. 421-427
Authors:
TRIPPOLI S
BECAGLI P
MESSORI A
TENDI E
Citation: S. Trippoli et al., MAINTENANCE TREATMENT WITH INTERFERON IN MULTIPLE-MYELOMA - A SURVIVAL METAANALYSIS, Clinical drug investigation, 14(5), 1997, pp. 392-399
Authors:
MESSORI A
BECAGLI P
BERTO V
TRIPPOLI S
FONT M
TOSOLINI F
VENTURINI F
MARTINI N
Citation: A. Messori et al., ADVANCED HIV-INFECTION TREATED WITH ZIDOVUDINE MONOTHERAPY - LIFETIMEVALUES OF ABSOLUTE COST-EFFECTIVENESS AS A PHARMACOECONOMIC REFERENCEFOR FUTURE STUDIES EVALUATING ANTIRETROVIRAL COMBINATION TREATMENTS, The Annals of pharmacotherapy, 31(12), 1997, pp. 1447-1454
Authors:
DAVINI I
BECAGLI P
PANI M
TRIPPOLI S
PEVERINI D
MESSORI A
CARMIGNANI A
Citation: I. Davini et al., COST-EFFECTIVENESS OF NEOADJUVANT MULTIMODAL THERAPY IN PATIENTS WITHESOPHAGEAL ADENOCARCINOMA, Oncology Reports, 4(5), 1997, pp. 1033-1037
Authors:
MESSORI A
BECAGLI P
TRIPPOLI S
TENDI E
Citation: A. Messori et al., A RETROSPECTIVE COST-EFFECTIVENESS ANALYSIS OF INTERFERON AS ADJUVANTTHERAPY IN HIGH-RISK RESECTED CUTANEOUS MELANOMA, European journal of cancer, 33(9), 1997, pp. 1373-1379
Authors:
MESSORI A
BECAGLI P
TRIPPOLI S
Citation: A. Messori et al., MEDIAN VERSUS MEAN LIFETIME SURVIVAL IN THE ANALYSIS OF SURVIVAL-DATA, Haematologica, 82(6), 1997, pp. 730-730
Authors:
TRIPPOLI S
BECAGLI P
MESSORI A
Citation: S. Trippoli et al., ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE AND FLUOROURACIL FOR NODE-POSITIVE BREAST-CANCER - A LIFETIME COST-UTILITY ANALYSIS BASED ON A MODIFIED Q-TWIST METHOD, European Journal of Clinical Pharmacology, 53(3-4), 1997, pp. 281-282
Authors:
MESSORI A
BECAGLI P
TRIPPOLI S
TENDI E
Citation: A. Messori et al., COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE PLUS METHOTREXATE PLUS FLUOROURACIL IN PATIENTS WITH NODE-POSITIVE BREAST-CANCER (VOL 51, PG 111, 1996), European Journal of Clinical Pharmacology, 51(5), 1997, pp. 427-427
Authors:
MESSORI A
CECCHI M
BECAGLI P
TRIPPOLI S
Citation: A. Messori et al., PHARMACOECONOMIC PROFILE OF PACLITAXEL AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED OVARIAN-CARCINOMA - A LIFETIME COST-EFFECTIVENESS ANALYSIS, Cancer, 79(11), 1997, pp. 2264-2266
Authors:
MESSORI A
BECAGLI P
TRIPPOLI S
Citation: A. Messori et al., COST-EFFECTIVENESS OF INTERFERON-ALPHA AS MAINTENANCE THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA, Annals of internal medicine, 126(8), 1997, pp. 664-664
Authors:
MESSORI A
TRIPPOLI S
TENDI E
Citation: A. Messori et al., G-CSF FOR THE PROPHYLAXIS OF NEUTROPENIC FEVER IN PATIENTS WITH SMALL-CELL LUNG-CANCER RECEIVING MYELOSUPPRESSIVE ANTINEOPLASTIC CHEMOTHERAPY - METAANALYSIS AND PHARMACOECONOMIC EVALUATION, Journal of clinical pharmacy and therapeutics, 21(2), 1996, pp. 57-63
Authors:
MESSORI A
BECAGLI P
TRIPPOLI S
TENDI E
Citation: A. Messori et al., COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE PLUS METHOTREXATE PLUS FLUOROURACIL IN PATIENTS WITH NODE-POSITIVE BREAST-CANCER, European Journal of Clinical Pharmacology, 51(2), 1996, pp. 111-116
Authors:
MESSORI A
TRIPPOLI S
BECAGLI P
TENDI E
Citation: A. Messori et al., PHARMACOECONOMIC PROFILE OF PACLITAXEL AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED OVARIAN-CARCINOMA - A LIFETIME COST-EFFECTIVENESS ANALYSIS, Cancer, 78(11), 1996, pp. 2366-2373
Risultati:
1-17
|